Shots:

• REGENXBIO plans to construct a cGMP manufacturing facility in Rockville- Maryland to produce gene therapy vectors based on NAV technology at scales up to 2-000L using its platform suspension cell culture process
• The addition of new cGMP manufacturing facility complements current external manufacturing capabilities- enabling a supply of NAV vectors from both internal and external sources meeting global regulatory requirements and is expected to be operational in 2021
• REGENXBIO's NAV technology is a gene delivery platform contains an exclusive right to 100+ novel AAV vectors including AAV7- AAV8- AAV9 and AAVrh10 and is used to develop therapies for multiple indications

Ref: REGENXBIO | Image: Solebury Trout Access